A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer

被引:9
|
作者
Poel, Dennis [1 ,2 ]
Gootjes, Elske C. [1 ,2 ]
Bakkerus, Lotte [1 ,2 ]
Trypsteen, Wim [3 ,4 ]
Dekker, Henk [1 ]
van der Vliet, Hans J. [1 ]
van Grieken, Nicole C. T. [5 ]
Verhoef, Cornelis [6 ]
Buffart, Tineke E. [1 ,7 ]
Verheul, Henk M. W. [1 ,2 ]
机构
[1] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands
[3] Univ Ghent, Fac Med & Hlth Sci, HIV Cure Res Ctr, Dept Internal Med & Pediat, Ghent, Belgium
[4] Ghent Univ Hosp, Ghent, Belgium
[5] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands
[6] Erasmus MC Canc Inst, Div Surg Oncol, Dept Surg, Rotterdam, Netherlands
[7] Dept Gastrointestinal Oncol, Amsterdam, Netherlands
来源
CANCER MEDICINE | 2020年 / 9卷 / 20期
关键词
chemotherapy; colorectal cancer; metastases; miRNA; response prediction; serum; FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; CIRCULATING MICRORNAS; FRESH-FROZEN; OPEN-LABEL; EXPRESSION; FLUOROURACIL; CHEMOTHERAPY; COMBINATION; LEUCOVORIN;
D O I
10.1002/cam4.3371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently needed. Therefore, a previously developed tissue-derived microRNA profile to predict clinical benefit from chemotherapy was evaluated in tissue biopsies and serum from patients with mCRC. Methods Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5-FU/LV with oxaliplatin +/- bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were quantified with RT-qPCR and droplet digital PCR, respectively. Combined predictive performance of selected variables was tested using logistic regression analysis. Results From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 serum samples were available. Based on expression levels of miRNAs in tissue, progressive disease could be predicted with an AUC of 0.85 (95% CI:0.72-0.91) and response could be predicted with an AUC of 0.70 (95% CI:0.56-0.80). This did not outperform clinical parameters alone (respectivelyP = .14 andP = .27). Expression levels of miR-92a-3p and miR-98-5p in serum significantly improved the predictive value of clinical parameters for response to chemotherapy (AUC 0.74, 95% CI:0.64-0.84,P = .003) in this cohort. Conclusions The additive predictive value to clinical parameters of the tissue-derived six miRNA profile for clinical benefit could not be validated in patients with mCRC treated with first-line systemic therapy. Although miR-92a-3p and miR-98-5p serum levels improved the predictive value of clinical parameters, it remained insufficient for clinical decision-making.
引用
收藏
页码:7558 / 7571
页数:14
相关论文
共 50 条
  • [31] Metastatic Colorectal Cancer: Prognostic and Predictive Factors
    Nappi, Anna
    Nasti, Guglielmo
    Romano, Carmela
    Berretta, Assimiliano
    Ottaiano, Alessandro
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (17) : 2779 - 2791
  • [32] Use of bevacizumab in the treatment of metastatic colorectal cancer
    Raouf, Sherif
    Bridgewater, John
    Ellis, Richard
    Ferry, David
    Hill, Mark
    Wasan, Harpreet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (01) : 25 - 30
  • [33] Apatinib as an optional treatment in metastatic colorectal cancer
    Li, Aiyi
    Wang, Kong
    Xu, Aiguo
    Wang, Gang
    Miao, Yongchang
    Sun, Zhichao
    Zhang, Jingyu
    MEDICINE, 2019, 98 (35) : e16919
  • [34] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [35] Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
    Hansen, T. F.
    Carlsen, A. L.
    Heegaard, N. H. H.
    Sorensen, F. B.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2015, 112 (04) : 624 - 629
  • [36] SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
    Aranda, E.
    Aparicio, J.
    Alonso, V.
    Garcia-Albeniz, X.
    Garcia-Alfonso, P.
    Salazar, R.
    Valladares, M.
    Vera, R.
    Vieitez, J. M.
    Garcia-Carbonero, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (12) : 972 - 981
  • [37] The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment
    Tokarz, Paulina
    Blasiak, Janusz
    ACTA BIOCHIMICA POLONICA, 2012, 59 (04) : 467 - 474
  • [38] The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
    Torben Frøstrup Hansen
    Flemming Brandt Sørensen
    Jan Lindebjerg
    Anders Jakobsen
    BMC Cancer, 12
  • [39] KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib
    Smith, John C.
    Brooks, Laura
    Hoff, Paulo M.
    McWalter, Gael
    Dearden, Simon
    Morgan, Shethah R.
    Wilson, David
    Robertson, Jane D.
    Juergenmeier, Juliane M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (10) : 2424 - 2432
  • [40] Risk Factors and Adequate Management for Complications of Bevacizumab Treatment Requiring Surgical Intervention in Patients With Metastatic Colorectal Cancer
    Bong, Jun Woo
    Lee, Jong Lyul
    Kim, Chan Wook
    Yoon, Yong Sik
    Park, In Ja
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Tae Won
    Kim, Jin Cheon
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E639 - E645